TTA-A8
TTA-A8 (Compound 13) is a short-acting T-type calcium channel antagonist with oral activity, exhibiting an IC50 value of 31.3 nM in the FLIPR depolarization assay. TTA-A8 possesses favorable pharmacokinetic properties, making it suitable for research on epilepsy and sleep[1].
Product Specifications
CAS Number
1146395-46-1
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Calcium Channel
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/tta-a8.html
Solubility
10 mM in DMSO
Smiles
CC1=NC=CN=C1C2=CC=C(C=C2)CC(N[C@@H](C3=CC=C(C=N3)OCC(F)(F)F)C)=O
Molecular Formula
C22H21F3N4O2
Molecular Weight
430.42
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501
References & Citations
[1]Yang Z Q, et al. Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents[J]. ACS Medicinal Chemistry Letters, 2010, 1 (9) : 504-509.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LY431634 100 µg
SAPS3 (PPP6R3) (NM_001164160) Human Over-expression Lysate
Sign In for Pricing
View Details 
